MedTrace Logo

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

NCT04652479 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-06-09

Study results available
· View outcomes & findings →

Summary

The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.

Conditions

  • Acquired Hyperinsulinemic Hypoglycemia

Interventions

DRUG

Avexitide

Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor

Sponsors & Collaborators

  • Eiger BioPharmaceuticals

    collaborator INDUSTRY

  • Dr. Tracey McLaughlin, MD

    lead OTHER

Principal Investigators

  • Marilyn Tan, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652479 on ClinicalTrials.gov